The North America albinism drug market is developing around a growing research pipeline aimed at addressing the underlying biological mechanisms of inherited pigment disorders. Drug-development efforts are moving beyond supportive management toward approaches targeting melanin pathways and genetic causes, although clinical evidence remains limited. This research activity, together with...